The Controlled Substances Act of 1970 created the DEA and a quota system intended to regulate dangerous substances. However, for cannabis, this system hinders research and patient access to therapies. The quotas are often low, arbitrarily enforced, and discourage scientific exploration. Despite legalization in many states, cannabis remains classified as a Schedule I drug, complicating research efforts. Consequently, patients cannot access necessary cannabis therapies, while researchers face significant bureaucratic hurdles, ultimately affecting public health and patient care.
The quota system has been used to block promising research and stall FDA-approved clinical trials, while benefiting a few outdated suppliers. Cannabinoid patients suffer access issues.
Sick patients are unable to access life-saving cannabis-based therapies due to the bureaucratic limitations of the quota system, which enforces laughably low production limits.
#cannabis-regulation #dea-quota-system #medical-marijuana #research-limitations #controlled-substances-act
Collection
[
|
...
]